---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-117217"
form_type: "8-K"
ticker: "CYPH"
cik: "0001509745"
company_name: "CYPHERPUNK TECHNOLOGIES INC."
filed_at: "2024-11-13T23:59:59+00:00"
generated_at: "2026-05-30T00:53:36.238498+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Leap Therapeutics Q3 net loss $18.2M; DKN-01 CRC enrollment complete, data mid-2025

## Summary
- Net loss of $18.2M for Q3 2024, up from $13.7M YoY, driven by higher R&D expenses.
- R&D expenses $14.9M (vs $11.5M); G&A $2.9M (vs $3.3M); cash $62.8M at Sept 30, 2024.
- Completed enrollment (188 patients) in Part B of DeFianCe study (DKN-01 in CRC); initial data expected mid-2025.
- DisTinGuish study (GEJ/gastric) Part C follow-up ongoing; initial data late 2024 or early 2025.
- Initiated development of FL-501, an anti-GDF-15 antibody for cachexia; promising preclinical data.

## SEC filing metadata
- accession: 0001104659-24-117217
- form_type: 8-K
- ticker: CYPH
- cik: 0001509745
- company_name: CYPHERPUNK TECHNOLOGIES INC.
- filed_at: 2024-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1509745/000110465924117217/0001104659-24-117217-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1509745/000110465924117217/tm2428221d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-117217
- JSON: https://secwatch.observer/filing/0001104659-24-117217.json
- Plain text: https://secwatch.observer/filing/0001104659-24-117217.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.